JP2017178934A - Vitamin d3-stabilizing composition - Google Patents
Vitamin d3-stabilizing composition Download PDFInfo
- Publication number
- JP2017178934A JP2017178934A JP2017050255A JP2017050255A JP2017178934A JP 2017178934 A JP2017178934 A JP 2017178934A JP 2017050255 A JP2017050255 A JP 2017050255A JP 2017050255 A JP2017050255 A JP 2017050255A JP 2017178934 A JP2017178934 A JP 2017178934A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- lecithin
- composition
- cholecalciferol
- soybean lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 229940088594 vitamin Drugs 0.000 title description 6
- 229930003231 vitamin Natural products 0.000 title description 6
- 235000013343 vitamin Nutrition 0.000 title description 6
- 239000011782 vitamin Substances 0.000 title description 6
- 150000003722 vitamin derivatives Chemical class 0.000 title description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 55
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 55
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 51
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 51
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 51
- 239000000787 lecithin Substances 0.000 claims abstract description 32
- 235000010445 lecithin Nutrition 0.000 claims abstract description 32
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 22
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 22
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 21
- 229940067606 lecithin Drugs 0.000 claims abstract description 21
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 11
- 235000009566 rice Nutrition 0.000 claims abstract description 11
- 229940005741 sunflower lecithin Drugs 0.000 claims abstract description 10
- 240000007594 Oryza sativa Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 11
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 claims description 10
- 235000021318 Calcifediol Nutrition 0.000 claims description 10
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 241000209094 Oryza Species 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 4
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229960002061 ergocalciferol Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 235000001892 vitamin D2 Nutrition 0.000 description 4
- 239000011653 vitamin D2 Substances 0.000 description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BWFQMABKLLTETH-YGQRWWDYSA-N (1S)-1,25-dihydroxy-24-oxocalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(=O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BWFQMABKLLTETH-YGQRWWDYSA-N 0.000 description 1
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- SNOXQOOPUCMFPS-IBLPRGGXSA-N (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r,5r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C SNOXQOOPUCMFPS-IBLPRGGXSA-N 0.000 description 1
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- WMYIVSWWSRCZFA-RWVJFQLJSA-N 1,25-Dihydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)[C@H]1C[C@@](C)(O)C(=O)O1 WMYIVSWWSRCZFA-RWVJFQLJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- IJNDMZIDDKVXHR-MYEQSZOMSA-N 25-Hydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C/1C(CC[C@@H](O)C\1)=C)C)[C@@H]1C[C@@](C)(O)C(=O)O1 IJNDMZIDDKVXHR-MYEQSZOMSA-N 0.000 description 1
- DDZHNKIBJQESJA-AHMPPUFCSA-N 25-hydroxy-24-oxocalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(=O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C DDZHNKIBJQESJA-AHMPPUFCSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Images
Abstract
Description
本発明は、ビタミンＤ３安定化組成物に関する。 The present invention relates to a vitamin D3 stabilizing composition.
ビタミンＤ（ｖｉｔａｍｉｎ Ｄ）は、ビタミンの一種であり、脂溶性ビタミンに分類される。ビタミンＤはさらにビタミンＤ２（エルゴカルシフェロール、Ｅｒｇｏｃａｌｃｉｆｅｒｏｌ）とビタミンＤ３（コレカルシフェロール、Ｃｈｏｌｅｃａｌｃｉｆｅｒｏｌ）に分けられる。ビタミンＤ２は植物に、ビタミンＤ３は動物に多く含まれ、ヒトではビタミンＤ３が重要な働きを果たしている。
ビタミンＤ３（コレカルシフェロール）は、肝臓においてＣ２５の位置でヒドロキシ化の代謝を受け、２５−ヒドロキシコレカルシフェロール（別名：２５（ＯＨ）Ｄ３、カルシフェジオール）へと変化し肝細胞に貯えられ、必要なときにα−グロブリンと結合しリンパ液中に放出される。この代謝物を含めてビタミンＤ３として利用されている。
近年、このビタミンＤ３の代謝物である２５−ヒドロキシコレカルシフェロールの作用が注目を集めている。例えば筋肉の発達促進（特許文献１）、高血糖の改善（特許文献２）、生殖能力の改善（特許文献３）、エオタキシンの増加に伴って発症するアレルギー疾患の改善（特許文献４）などが代表的である。
また、その他の新たな用途開発も始まっている。
Vitamin D (vitamin D) is a kind of vitamin and is classified as a fat-soluble vitamin. Vitamin D is further divided into vitamin D2 (Ergocalciferol, Ergocalciferol) and Vitamin D3 (Cholecalciferol). Vitamin D2 is abundant in plants and vitamin D3 is abundant in animals, and vitamin D3 plays an important role in humans.
Vitamin D3 (cholecalciferol) undergoes hydroxylation metabolism at the C25 position in the liver, changes to 25-hydroxycholecalciferol (also known as 25 (OH) D3, calciferdiol) and is stored in hepatocytes. When necessary, it binds to α-globulin and is released into the lymph. This metabolite is used as vitamin D3.
In recent years, the action of 25-hydroxycholecalciferol, which is a metabolite of vitamin D3, has attracted attention. For example, promotion of muscle development (Patent Document 1), improvement of hyperglycemia (Patent Document 2), improvement of fertility (Patent Document 3), improvement of allergic diseases that develop with an increase in eotaxin (Patent Document 4), etc. Representative.
Other new application developments have also begun.
一方、２５−ヒドロキシコレカルシフェロールやコレカルシフェロールは、化学的に極めて不安定なことが知られている。特に酸化による影響が大きい。通常、空気中で酸化されてその活性を速やかに消失することが知られている。特許文献５には、ビタミンＤと油成分、ポリグリセリン脂肪酸エステル多価アルコールを含む安定なマイクロエマルジョンの技術が開示されている。特許文献６には、活性型ビタミンＤ類を塩基性高分子物質中に分散してなる安定化組成物が記載されている。 On the other hand, 25-hydroxycholecalciferol and cholecalciferol are known to be extremely unstable chemically. The influence by oxidation is particularly large. It is generally known that it is oxidized in the air and its activity disappears quickly. Patent Document 5 discloses a technique of a stable microemulsion containing vitamin D, an oil component, and a polyglycerol fatty acid ester polyhydric alcohol. Patent Document 6 describes a stabilized composition obtained by dispersing active vitamin Ds in a basic polymer substance.
本発明者らは、活性型である２５−ヒドロキシコレカルシフェロールの安定化を研究しているが、２５−ヒドロキシコレカルシフェロールやビタミンＤ３（コレカルシフェロール）が特定の乳化剤成分を共存させることで安定性が増加する現象を見いだし、本発明を
完成させた。
The present inventors are studying stabilization of the active form of 25-hydroxycholecalciferol, but 25-hydroxycholecalciferol and vitamin D3 (cholecalciferol) are allowed to coexist with a specific emulsifier component. The phenomenon of increased stability was found and the present invention was completed.
すなわち、本発明は、ビタミンＤ３が安定化された組成物を提供することを課題とする。 That is, an object of the present invention is to provide a composition in which vitamin D3 is stabilized.
本発明の主な構成は以下の通りである。
１．ビタミンＤ３と、大豆レシチン、酵素分解大豆レシチン、ライスレシチンオイル、ヒマワリレシチンから選択される１以上のレシチンからなる組成物。
２．ビタミンＤ３がコレカルシフェロール及び／又は活性型ビタミンＤ３である１に記載の組成物。
３．活性型ビタミンＤ３が２５−ヒドロキシコレカルシフェロールである２に記載の組成物。
４．大豆レシチン、酵素分解大豆レシチン、ライスレシチンオイル、ヒマワリレシチンから選択される１以上のレシチン１０００質量部当たりビタミンＤ３を０．１〜１０質量部含む１〜３のいずれかに記載の組成物。
５．大豆レシチン、酵素分解大豆レシチン、ライスレシチンオイル、ヒマワリレシチンから選択される１以上のレシチンとビタミンＤ３のエタノール溶液を混合し、ついでエタノールを含む混合溶液を減圧乾燥することを特徴とするビタミンＤ３の安定化組成物を製造する方法。
The main configuration of the present invention is as follows.
1. A composition comprising vitamin D3 and at least one lecithin selected from soybean lecithin, enzyme-degraded soybean lecithin, rice lecithin oil, and sunflower lecithin.
2. 2. The composition according to 1, wherein the vitamin D3 is cholecalciferol and / or active vitamin D3.
3. 3. The composition according to 2, wherein the active vitamin D3 is 25-hydroxycholecalciferol.
4). The composition in any one of 1-3 which contains 0.1-10 mass parts of vitamin D3 per 1000 mass parts of 1 or more lecithin selected from soybean lecithin, enzyme-degraded soybean lecithin, rice lecithin oil, and sunflower lecithin.
5). One or more lecithins selected from soybean lecithin, enzyme-degraded soybean lecithin, rice lecithin oil and sunflower lecithin are mixed with an ethanol solution of vitamin D3, and then the ethanol-containing mixed solution is dried under reduced pressure. A method for producing a stabilizing composition.
本発明によりビタミンＤ３が安定化された組成物を提供できる。本発明により得られた組成物は、ビタミンＤ３が長時間安定である。また本発明の組成物は、水にも油にも溶解又は分散するため、食品や医薬品の原料として極めて有用である。 According to the present invention, a composition in which vitamin D3 is stabilized can be provided. In the composition obtained according to the present invention, vitamin D3 is stable for a long time. Moreover, since the composition of the present invention dissolves or disperses in water and oil, it is extremely useful as a raw material for foods and pharmaceuticals.
本発明は、ビタミンＤ３と、レシチンからなる組成物に係る発明である。
本発明に用いられるビタミンＤ３は、コレカルシフェロール及び／又は活性型ビタミンＤ３類である。
活性型ビタミンＤ３類としては１α，２５−（ＯＨ）２−Ｄ３（２５−ヒドロキシコレカルシフェロール）、１α−ヒドロキシビタミンＤ３（１α−ＯＨ−Ｄ３）、１α，２５−ジヒドロキシビタミンＤ３（１α，２５−（ＯＨ）２−Ｄ３）、１α，２４−ジヒドロキシビタミンＤ３（１α，２４−（ＯＨ）２−Ｄ３）、１α，２４，２５−トリヒドロキシビタミンＤ３（１α，２４，２５−（ＯＨ）３−Ｄ３）、１α−ヒドロキシ−２４−オキソビタミンＤ３、１α，２５−ジヒドロキシ−２４−オキソビタミンＤ３、１α，２５−ジヒドロキシビタミンＤ３−２６，２３−ラクトン、１α，２５−ジヒドロキシビタミンＤ３−２６，２３−パーオキシラクトン、２６，２６，２６，２７，２７，２７−ヘキサフルオロ−１α，２５−ジヒドロキシビタミンＤ３などの１α位に水酸基を有する活性型ビタミンＤ３類、あるいは２５−ヒドロキシビタミンＤ３（２５−ＯＨ−Ｄ３）、２４−ヒドロキシビタミンＤ３（２４−ＯＨ−Ｄ３）、２４−オキソビタミンＤ３、２４，２５−ジヒドロキシビタミンＤ３（２４，２５−（ＯＨ）２−Ｄ３）、２５−ヒドロキシ−２４−オキソビタミンＤ３、２５−ヒドロキシビタミンＤ３−２６，２３−ラクトン、２５−ヒドロキシビタミンＤ３−２６，２３−パーオキシラクトンなどの１α位に水酸基を有しない活性型ビタミンＤ３類などが挙げられる。
The present invention relates to a composition comprising vitamin D3 and lecithin.
Vitamin D3 used in the present invention is cholecalciferol and / or active vitamin D3.
The active vitamin D3s are 1α, 25- (OH) 2-D3 (25-hydroxycholecalciferol), 1α-hydroxyvitamin D3 (1α-OH-D3), 1α, 25-dihydroxyvitamin D3 (1α, 25 -(OH) 2-D3), 1α, 24-dihydroxyvitamin D3 (1α, 24- (OH) 2-D3), 1α, 24,25-trihydroxyvitamin D3 (1α, 24,25- (OH) 3 -D3), 1α-hydroxy-24-oxovitamin D3, 1α, 25-dihydroxy-24-oxovitamin D3, 1α, 25-dihydroxyvitamin D3-26,23-lactone, 1α, 25-dihydroxyvitamin D3-26, 23-peroxylactone, 26,26,26,27,27,27-hexafluoro-1α, 25-dihydroxybi Active vitamin D3 having a hydroxyl group at the 1α position such as Tamine D3, or 25-hydroxyvitamin D3 (25-OH-D3), 24-hydroxyvitamin D3 (24-OH-D3), 24-oxovitamin D3, 24 , 25-dihydroxyvitamin D3 (24,25- (OH) 2-D3), 25-hydroxy-24-oxovitamin D3, 25-hydroxyvitamin D3-26,23-lactone, 25-hydroxyvitamin D3-26,23 -Active vitamin D3 having no hydroxyl group at the 1α position, such as peroxylactone.
これらの活性型ビタミンＤ３類の中でも１α，２５−（ＯＨ）２−Ｄ３（２５−ヒドロキシコレカルシフェロール又は「２５（ＯＨ）Ｄ３」）が好ましい。 Among these active vitamins D3, 1α, 25- (OH) 2-D3 (25-hydroxycholecalciferol or “25 (OH) D3”) is preferable.
本発明で用いる大豆レシチンとは、大豆油を得る工程で、脱ガム工程によって得られる水和物であり、レシチンとその他リン脂質を含む。本発明においては食品や医薬品の乳化剤として利用可能な程度に脱色、精製されたものであれば使用可能である。
酵素分解大豆レシチンとは、リゾレシチンとも呼ばれ、大豆レシチンを酵素処理したものである。大豆レシチンと同様に食品や医薬品の乳化剤として利用可能な程度に脱色、精製されたものであれば使用可能である。
ライスレシチンオイルとは、米油精製工程において、大豆レシチンと同様に脱ガム工程によって得られる水和物であり、レシチンとその他リン脂質を含む。本発明においては食品や医薬品の乳化剤として利用可能な程度に脱色、精製されたものであれば使用可能である。
ヒマワリレシチンは、ヒマワリ油精製工程において、大豆レシチンと同様に脱ガム工程によって得られる水和物であり、レシチンとその他リン脂質を含む。本発明においては食品や医薬品の乳化剤として利用可能な程度に脱色、精製されたものであれば使用可能である。
The soy lecithin used in the present invention is a hydrate obtained by a degumming step in the step of obtaining soybean oil, and includes lecithin and other phospholipids. In the present invention, any material that has been decolorized and purified to the extent that it can be used as an emulsifier for foods and pharmaceuticals can be used.
Enzyme-degraded soybean lecithin is also called lysolecithin and is obtained by enzymatic treatment of soybean lecithin. Similar to soybean lecithin, any product that has been decolorized and purified to the extent that it can be used as an emulsifier for foods and pharmaceuticals can be used.
Rice lecithin oil is a hydrate obtained by a degumming process in the same manner as soybean lecithin in the rice oil refining process, and contains lecithin and other phospholipids. In the present invention, any material that has been decolorized and purified to the extent that it can be used as an emulsifier for foods and pharmaceuticals can be used.
Sunflower lecithin is a hydrate obtained by a degumming step in the same manner as soybean lecithin in the sunflower oil refining step, and contains lecithin and other phospholipids. In the present invention, any material that has been decolorized and purified to the extent that it can be used as an emulsifier for foods and pharmaceuticals can be used.
本発明の組成物を得るためには、ビタミンＤ３をエタノールなどの溶媒に溶解させる。溶媒としては水又はエタノールが好ましい。この溶解液を大豆レシチン、酵素分解大豆レシチン、ライスレシチンオイル、ヒマワリレシチンから選択される１以上のレシチン（以
下「レシチン類」）と均質に混合し、混合終了後ビタミンＤ３を含むレシチン類を乾燥装置で乾燥させて溶媒を除去することで得ることができる。混合に当たっては、ビタミンＤ３が可能な限り小粒子として分散されるように混合する。必要に応じて高圧ホモジナイザーを用いることもできる。乾燥にあたっては、できるだけ低温で行うことが好ましく、真空凍結乾燥や減圧乾燥などの方法を採用することがより好ましい。
To obtain the composition of the present invention, vitamin D3 is dissolved in a solvent such as ethanol. As the solvent, water or ethanol is preferable. This solution is homogeneously mixed with one or more lecithins selected from soybean lecithin, enzyme-degraded soybean lecithin, rice lecithin oil, and sunflower lecithin (hereinafter referred to as “lecithins”). It can obtain by drying with an apparatus and removing a solvent. In mixing, vitamin D3 is mixed so that it is dispersed as small particles as possible. A high-pressure homogenizer can also be used as necessary. Drying is preferably performed at a temperature as low as possible, and it is more preferable to employ a method such as vacuum freeze drying or reduced pressure drying.
レシチン類とビタミンＤ３は、レシチン類１０００質量部当たりコレカルシフェロール及び／又は２５−ヒドロキシコレカルシフェロール（２５（ＯＨ）Ｄ３）を０．１〜１０質量部の比率となるようにすることが好ましい。
かくして得られる組成物は、レシチン中にビタミンがＤ３が分散した状態であって、レシチン類が溶解分散可能な水や油に速やかに溶解する。
またこの組成物は、澱粉や糖を加えて粉末とすることも可能である。
It is preferable that the lecithins and vitamin D3 have a ratio of 0.1 to 10 parts by mass of cholecalciferol and / or 25-hydroxycholecalciferol (25 (OH) D3) per 1000 parts by mass of the lecithin. .
In the composition thus obtained, vitamin D3 is dispersed in lecithin, and lecithins dissolve rapidly in water or oil that can be dissolved and dispersed.
The composition can also be powdered by adding starch or sugar.
以下に試験例を示し、本発明を説明する。
レシチン類によるビタミンＤ３の安定性試験
（１）ビタミンＤ３
下記の表１に示すビタミンＤ３を用いて試験をおこなった。
Test examples are shown below to explain the present invention.
Vitamin D3 stability test with lecithins (1) Vitamin D3
A test was conducted using vitamin D3 shown in Table 1 below.
（２）使用レシチン類
市販の下記の表２に示すレシチン類を試験に用いた。
(2) Used lecithins Commercially available lecithins shown in Table 2 below were used in the test.
（３）試験方法
＜試料の調製＞
１）コレカルシフェロールの調製
市販のコレカルシフェロール結晶１７５μｇを無水エタノール１７５０ｍｇに溶解させ溶液とした。
この溶液１．７５ｇを、バイアル瓶に予め秤量してあった各レシチン類１ｇに加え、ボルテックスミキサーを用いて３分間撹拌混合した。その後、エタノールを減圧乾燥して除去し試料を得た。
(3) Test method <Sample preparation>
1) Preparation of cholecalciferol 175 μg of commercially available cholecalciferol crystals were dissolved in 1750 mg of absolute ethanol to obtain a solution.
1.75 g of this solution was added to 1 g of each lecithin previously weighed in a vial and stirred and mixed for 3 minutes using a vortex mixer. Thereafter, ethanol was removed by drying under reduced pressure to obtain a sample.
２）２５（ＯＨ）Ｄ３の調製
（２５（ＯＨ）Ｄ３）１０．２０５ｍｇを無水エタノール５００ｇに溶解させ溶液とした。この溶液２．５ｇをバイアル瓶に予め秤量してあった各レシチン類１ｇに加え、ボルテックスミキサーを用いて３分間撹拌混合した。その後、エタノールを減圧乾燥し試料を得た。
2) Preparation of 25 (OH) D3 10.205 mg of (25 (OH) D3) was dissolved in 500 g of absolute ethanol to obtain a solution. 2.5 g of this solution was added to 1 g of each lecithin previously weighed in a vial and stirred and mixed for 3 minutes using a vortex mixer. Thereafter, ethanol was dried under reduced pressure to obtain a sample.
３）安定性試験
上記試料を６０℃の恒温槽で２週間保存し、ビタミンＤ３の残存率を測定した。
＜コレカルシフェロールの分析方法＞
１．コレカルシフェロール含有試料約０．０１ｇを精密に量り、２０ｍＬ程度の容器に入れ、１０ｍＬのホールピペットにてエタノールを加え撹拌し、５分間超音波にかけ撹拌後約１ｍＬをエッペンチューブに採取し、１５０００ｐｒｍ ５分間遠心する。上清を試料溶液とする。
２．コレカルシフェロール標準品を１ｍｇ／ｍＬとなるようエタノールにて調整後、０．１、０．５、１．０、５．０、１０．０μｇ／ｍＬとなるようエタノール溶液にて適宜希釈し、標準溶液とする。
試料溶液及び標準溶液それぞれ１０μＬを以下の条件の高速液体クロマトグラフィーに注入し、コレカルシフェロールのピーク面積を求め、標準溶液のコレカルシフェロールのピーク面積から検量線（ｙ＝ｂｘ＋ａ：ａ＝切片、ｂ＝傾き）を求め、下記に示した計算法に従って試料のコレカルシフェロールの含量を求める。
３．測定条件
検出器 ： 紫外吸光光度計（測定波長 ２６５ｎｍ）
カラム ： 内径４．６ｍｍ、長さ２５０ｍｍのステンレス管に粒径５μｍのオクタデシル化シリカゲルを充填したもの（Ｃａｐｃｅｌｌｐａｋ Ｃ−１８ ＵＧ−１２０ 株式会社資生堂製）
カラム温度： ４０℃
移動相 ： ８０％アセトニトリル水溶液
流速 ： １ｍＬ／分
４．計算法
コレカルシフェロール含量（μｇ／ｇ）＝（試料溶液のコレカルシフェロール面積−切片）／傾き×定容量／試料採取量×純度
3) Stability test The said sample was preserve | saved for two weeks in a 60 degreeC thermostat, and the residual rate of vitamin D3 was measured.
<Method of analyzing cholecalciferol>
1. About 0.01 g of cholecalciferol-containing sample is precisely weighed, placed in a container of about 20 mL, added with ethanol with a 10 mL hole pipette, stirred, subjected to ultrasonic wave for 5 minutes, and after stirring, about 1 mL was collected in an Eppendorf tube, and 15000 prm Centrifuge for 5 minutes. Use the supernatant as the sample solution.
2. After adjusting the cholecalciferol standard product to 1 mg / mL with ethanol, appropriately dilute with ethanol solution to 0.1, 0.5, 1.0, 5.0, 10.0 μg / mL, Use standard solution.
10 μL each of the sample solution and the standard solution was injected into high performance liquid chromatography under the following conditions, the peak area of cholecalciferol was determined, and a calibration curve (y = bx + a: a = intercept, from the peak area of cholecalciferol in the standard solution) b = slope), and the cholecalciferol content of the sample is determined according to the calculation method shown below.
3. Measurement condition detector: UV absorption photometer (measurement wavelength: 265 nm)
Column: A stainless steel tube with an inner diameter of 4.6 mm and a length of 250 mm filled with octadecylated silica gel having a particle size of 5 μm (Capcellpak C-18 UG-120, manufactured by Shiseido Co., Ltd.)
Column temperature: 40 ° C
Mobile phase: 80% aqueous acetonitrile flow rate: 1 mL / min Calculation method Cholecalciferol content (μg / g) = (cholecalciferol area of sample solution−intercept) / slope × constant volume / sample amount × purity
＜２５（ＯＨ）Ｄ３の分析方法＞
１．２５（ＯＨ）Ｄ３含有試料約０．１ｇを２０ｍＬ程度の容器に精密に量り、１０ｍＬのホールピペットにてエタノールを加え撹拌し、１０分間超音波にかけ撹拌後約１ｍＬをエッペンチューブに移し、１５０００ｐｒｍ ５分間遠心する。上清を試料溶液とする。
２．２５（ＯＨ）Ｄ３標準品を１ｍｇ／ｍＬとなるようエタノールにて調整後、０．１、０．２、０．５、１．０、２．０μｇ／ｍＬとなるようエタノール溶液にて適宜希釈し、標準溶液とする。試料溶液及び標準溶液それぞれ１０μＬを以下の条件の高速液体クロマトグラフィーに注入し、２５（ＯＨ）Ｄ３のピーク面積を求め、標準溶液の２５（ＯＨ）Ｄ３のピーク面積から検量線（ｙ＝ｂｘ＋ａ：ａ＝切片、ｂ＝傾き）を求め、下記に示した計算法に従って試料の２５（ＯＨ）Ｄ３含量を求める。
３．測定条件
検出器 ： 紫外吸光光度計（測定波長 ２６５ｎｍ）
カラム ： 内径４．６ｍｍ、長さ２５０ｍｍのステンレス管に粒径５μｍのオクタデシル化シリカゲルを充填したもの（Ｃａｐｃｅｌｌｐａｋ Ｃ−１８ ＵＧ−１２０ 株式会社資生堂製）
カラム温度： ４０℃
移動相 ： ８０％アセトニトリル水溶液
流速 ： １ｍＬ／分
４．計算法
２５（ＯＨ）Ｄ３含量（μｇ／ｇ）＝（試料溶液の２５（ＯＨ）Ｄ３面積−切片）／傾き×定容量／試料採取量×純度
<25 (OH) D3 Analysis Method>
About 0.1 g of 1.25 (OH) D3-containing sample is precisely weighed into a container of about 20 mL, ethanol is added with a 10 mL hole pipette, stirred, and ultrasonically stirred for 10 minutes, and then about 1 mL is transferred to an Eppendorf tube. Centrifuge at 15000 prm for 5 minutes. Use the supernatant as the sample solution.
2.25 (OH) D3 standard product is adjusted with ethanol to 1 mg / mL, and then with ethanol solution to 0.1, 0.2, 0.5, 1.0, 2.0 μg / mL. Dilute appropriately to make a standard solution. 10 μL each of the sample solution and the standard solution is injected into high performance liquid chromatography under the following conditions, the peak area of 25 (OH) D3 is obtained, and a calibration curve (y = bx + a: a = intercept, b = slope), and the 25 (OH) D3 content of the sample is determined according to the calculation method shown below.
3. Measurement condition detector: UV absorption photometer (measurement wavelength: 265 nm)
Column: A stainless steel tube with an inner diameter of 4.6 mm and a length of 250 mm filled with octadecylated silica gel having a particle size of 5 μm (Capcellpak C-18 UG-120, manufactured by Shiseido Co., Ltd.)
Column temperature: 40 ° C
Mobile phase: 80% aqueous acetonitrile flow rate: 1 mL / min Calculation method 25 (OH) D3 content (μg / g) = (25 (OH) D3 area of sample solution−intercept) / slope × constant volume / sampled amount × purity
（４）結果
各試料の安定性試験結果を表３及び図１に示す。なお結果は、保存期間経過後の残存率で表している。
(4) Results Table 3 and FIG. 1 show the stability test results of each sample. The results are expressed as the remaining rate after the storage period.
コレカルシフェロールは大豆レシチン及び酵素分解大豆レシチンにより安定化する。一方２５（ＯＨ）Ｄ３は、コレカルシフェロールとは異なり、酵素分解大豆レシチン、ヒマワリレシチン、ライスレシチンオイルによって安定化することが確認できた。
Cholecalciferol is stabilized by soy lecithin and enzymatically degraded soy lecithin. On the other hand, it was confirmed that 25 (OH) D3 was stabilized by enzymatically decomposed soybean lecithin, sunflower lecithin and rice lecithin oil, unlike cholecalciferol.
Claims (5)
One or more lecithins selected from soybean lecithin, enzyme-degraded soybean lecithin, rice lecithin oil and sunflower lecithin are mixed with an ethanol solution of vitamin D3, and then the ethanol-containing mixed solution is dried under reduced pressure. A method for producing a stabilizing composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016058562 | 2016-03-23 | ||
| JP2016058562 | 2016-03-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017178934A true JP2017178934A (en) | 2017-10-05 |
| JP6823511B2 JP6823511B2 (en) | 2021-02-03 |
Family
ID=60008441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017050255A Active JP6823511B2 (en) | 2016-03-23 | 2017-03-15 | Vitamin D3 stabilizing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6823511B2 (en) |
-
2017
- 2017-03-15 JP JP2017050255A patent/JP6823511B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6823511B2 (en) | 2021-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Higashi et al. | Advances in determination of vitamin D related compounds in biological samples using liquid chromatography–mass spectrometry: a review | |
| Hymøller et al. | Vitamin D analysis in plasma by high performance liquid chromatography (HPLC) with C30 reversed phase column and UV detection–easy and acetonitrile-free | |
| Ramakrishnan et al. | Fish oil microcapsules from O/W emulsions produced by premix membrane emulsification | |
| Millao et al. | Extraction of oil and carotenoids from pelletized microalgae using supercritical carbon dioxide | |
| Perez-Serradilla et al. | Simultaneous ultrasound-assisted emulsification− extraction of polar and nonpolar compounds from solid plant samples | |
| AU2005253732A1 (en) | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel | |
| JP2011127905A (en) | Method for determining quantity of carotenoid | |
| CA3044681A1 (en) | Emulsified fatty acids | |
| Di Mattia et al. | Effect of olive oil phenolic compounds and maltodextrins on the physical properties and oxidative stability of olive oil o/w emulsions | |
| JP6742487B1 (en) | Pharmaceutical composition containing eldecalcitol | |
| Yeadon et al. | Lecithin in oil-in-water emulsions | |
| JP2017178934A (en) | Vitamin d3-stabilizing composition | |
| JP5817067B2 (en) | Stabilized active compounds | |
| JP6851868B2 (en) | Vitamin D3 stabilizing composition | |
| Yildiz et al. | Investigation of curcumin water solubility through emulsifying with biocompatible polyethylene glycol–based polymers | |
| TW201511760A (en) | Powdery or solid composition containing acylated sterol glycosides and method for producing same | |
| JP6821435B2 (en) | Chromatographic material for separating unsaturated molecules | |
| JP6628927B1 (en) | Eldecalcitol soft capsule | |
| JP2017178932A (en) | Vitamin d3-stabilizing composition | |
| Garcia et al. | Microencapsulation of shark liver oil pool by spray drying | |
| Morales et al. | New analytical evidence of discontinuous oxidation in dried microencapsulated lipids | |
| Villegas et al. | A rapid and simple method for the analysis of bioactive compounds in olive oil refining by-products by liquid chromatography with ultraviolet and mass spectrometry detection | |
| Xie et al. | Chemical compositions and oxidative stabilities of Ginkgo biloba kernel oils from four cultivated regions in China | |
| SHIGA et al. | A simple method for determining the flaxseed or fish oil content with N, N-dimethylformamide in microcapsules prepared by spray drying | |
| EP2584913A1 (en) | Stabilized active compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191024 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201005 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201005 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6823511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |